Technical Analysis for SVRA - Savara, Inc.

Grade Last Price % Change Price Change
grade F 7.38 0.14% 0.01
SVRA closed up 0.14 percent on Friday, January 18, 2019, on 45 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical SVRA trend table...

Date Alert Name Type % Chg
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 Doji - Bullish? Reversal 0.00%
Jan 18 Stochastic Reached Oversold Weakness 0.00%
Jan 18 Oversold Stochastic Weakness 0.00%
Jan 17 20 DMA Resistance Bearish 0.14%
Jan 17 Doji - Bullish? Reversal 0.14%
Jan 16 Fell Below 20 DMA Bearish -0.27%
Jan 15 20 DMA Support Bullish -2.12%
Jan 15 Doji - Bullish? Reversal -2.12%

Older signals for SVRA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:

Profile
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Is SVRA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 16 Could The Savara Inc. (NASDAQ:SVRA) Ownership Structure Tell Us Something Useful?
Dec 26 55 Biggest Movers From Monday
Dec 24 Midday Gainers / Losers
Dec 24 Savara and CRISPR Therapeutics among healthcare gainers; EyePoint Pharmaceuticals and Novus Therapeutics among losers
Dec 22 Savara, Inc. (SVRA)Hedge Funds Are Snapping Up
Dec 20 The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum
Dec 19 Savara Announces Interim Results for OPTIMA Clinical Study of Molgradex for the Treatment of NTM
Dec 11 The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
Dec 7 The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
Nov 16 Savara to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27th
See more SVRA news...
Indicators
Indicator Value
52 Week High 14.06
52 Week Low 6.21
Average Volume 206,709
200-Day Moving Average 10.0293
50-Day Moving Average 8.1705
20-Day Moving Average 7.4715
10-Day Moving Average 7.631
Average True Range 0.4498
ADX 19.76
+DI 13.7451
-DI 19.0494
Chandelier Exit (Long, 3 ATRs ) 6.8206
Chandelier Exit (Short, 3 ATRs ) 7.5594
Upper Bollinger Band 8.342
Lower Bollinger Band 6.601
Percent B (%b) 0.45
BandWidth 23.30188
MACD Line -0.1411
MACD Signal Line -0.1704
MACD Histogram 0.0292
Fundamentals Value
Market Cap 178.62 Million
Num Shares 24.2 Million
EPS -3.50
Price-to-Earnings (P/E) Ratio -2.11
Price-to-Sales 526.42
Price-to-Book 2.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.64
Resistance 3 (R3) 7.64 7.55 7.59
Resistance 2 (R2) 7.55 7.49 7.55 7.58
Resistance 1 (R1) 7.47 7.45 7.47 7.47 7.56
Pivot Point 7.38 7.38 7.38 7.38 7.38
Support 1 (S1) 7.30 7.32 7.30 7.30 7.20
Support 2 (S2) 7.21 7.28 7.21 7.18
Support 3 (S3) 7.13 7.21 7.17
Support 4 (S4) 7.13